Literature DB >> 29844812

Downregulation of RIP140 in triple-negative breast cancer inhibits the growth and proliferation of cancer cells.

Xiao-Hong Yu1, Xiaodong Xue1, Xun Zhu2, Xia Li1.   

Abstract

The aim of the present study was to investigate the expression of receptor interacting protein 140 (RIP140) in triple-negative breast cancer (TNBC), and its association with the prognosis of patients with TNBC. A total of 179 patients with breast cancer were included in this study, with 41 cases of TNBC and 138 cases of non-TNBC. Immunohistochemical staining and western blotting were used to detect the protein expression of RIP140 in the cancerous and paracancerous tissues, revealing that expression of RIP140 was increased in TNBC tissues compared with non-TNBC tissues. High expression of RIP140 in breast cancer tissue was associated with a poorer survival time than low RIP140 expression. Using lentiviral transfection to downregulate RIP140 expression in MDA-MB-231 cells, the effects of RIP140 on the growth and proliferation of breast cancer cells was analyzed using subcutaneous tumors in BALB/c nude mice. Immunohistochemical staining using a Ki-67 antibody in subcutaneous tumor tissue was used to assess the proliferation of MDA-MB-231 cells. The short hairpin RNA-mediated downregulation of RIP140 in MDA-MB-231 cells suppressed the growth and the proliferation of subcutaneous tumors in BALB/c nude mice. Downregulation of RIP140 in breast cancer cells may therefore inhibit the growth and the proliferation of these cells, and may provide a therapeutic target for TNBC.

Entities:  

Keywords:  prognosis; proliferation; receptor interacting protein 140; triple-negative breast cancer

Year:  2018        PMID: 29844812      PMCID: PMC5958796          DOI: 10.3892/ol.2018.8434

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

1.  Downregulation of RIP140 in hepatocellular carcinoma promoted the growth and migration of the cancer cells.

Authors:  Dexiang Zhang; Yueqi Wang; Yuedi Dai; Jiwen Wang; Tao Suo; Hongtao Pan; Han Liu; Sheng Shen; Houbao Liu
Journal:  Tumour Biol       Date:  2014-11-13

Review 2.  Clinical practice. Breast-cancer screening.

Authors:  Ellen Warner
Journal:  N Engl J Med       Date:  2011-09-15       Impact factor: 91.245

3.  Prevalence and risk factors associated with pain 21 months following surgery for breast cancer.

Authors:  Niamh Moloney; Jennie Man Wai Sung; Sharon Kilbreath; Elizabeth Dylke
Journal:  Support Care Cancer       Date:  2016-06-07       Impact factor: 3.603

4.  The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes.

Authors:  Aurélie Docquier; Pierre-Olivier Harmand; Samuel Fritsch; Maïa Chanrion; Jean-Marie Darbon; Vincent Cavaillès
Journal:  Clin Cancer Res       Date:  2010-04-21       Impact factor: 12.531

5.  Changes in nuclear receptor corepressor RIP140 do not influence mitochondrial content in the cortex.

Authors:  Eric A F Herbst; Arend Bonen; Graham P Holloway
Journal:  Appl Physiol Nutr Metab       Date:  2015-07-10       Impact factor: 2.665

Review 6.  Breast cancer in China.

Authors:  Lei Fan; Kathrin Strasser-Weippl; Jun-Jie Li; Jessica St Louis; Dianne M Finkelstein; Ke-Da Yu; Wan-Qing Chen; Zhi-Ming Shao; Paul E Goss
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

7.  RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis.

Authors:  Marion Lapierre; Sandrine Bonnet; Caroline Bascoul-Mollevi; Imade Ait-Arsa; Stéphan Jalaguier; Maguy Del Rio; Michela Plateroti; Paul Roepman; Marc Ychou; Julie Pannequin; Frédéric Hollande; Malcolm Parker; Vincent Cavailles
Journal:  J Clin Invest       Date:  2014-03-25       Impact factor: 14.808

8.  NF-κB-mediated degradation of the coactivator RIP140 regulates inflammatory responses and contributes to endotoxin tolerance.

Authors:  Ping-Chih Ho; Yao-Chen Tsui; Xudong Feng; David R Greaves; Li-Na Wei
Journal:  Nat Immunol       Date:  2012-03-04       Impact factor: 25.606

9.  Suppressing NRIP1 inhibits growth of breast cancer cells in vitro and in vivo.

Authors:  Moammir H Aziz; Xundi Chen; Qi Zhang; Chad DeFrain; Jared Osland; Yizhou Luo; Xin Shi; Rong Yuan
Journal:  Oncotarget       Date:  2015-11-24

10.  Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.

Authors:  Pradip De; Jennifer H Carlson; Hui Wu; Adam Marcus; Brian Leyland-Jones; Nandini Dey
Journal:  Oncotarget       Date:  2016-07-12
View more
  2 in total

1.  The Transcription Coregulator RIP140 Inhibits Cancer Cell Proliferation by Targeting the Pentose Phosphate Pathway.

Authors:  Valentin Jacquier; Delphine Gitenay; Vincent Cavaillès; Catherine Teyssier
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

2.  RIP140 inhibits glycolysis-dependent proliferation of breast cancer cells by regulating GLUT3 expression through transcriptional crosstalk between hypoxia induced factor and p53.

Authors:  Vincent Cavaillès; Catherine Teyssier; Valentin Jacquier; Delphine Gitenay; Samuel Fritsch; Sandrine Bonnet; Balázs Győrffy; Stéphan Jalaguier; Laetitia K Linares
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.